Ravi Savarirayan,Josep Maria De Bergua,Paul Arundel,Jean‐Pierre Salles,Vrinda Saraff,Borja Delgado,Antonio Leiva-Gea,Helen McDevitt,Marc Nicolino,Massimiliano Rossi,M. Salcedo,Valérie Cormier‐Daire,Mars Skae,Pekka Kannus,John A. Phillips,Howard M. Saal,Paul Harmatz,Toby Candler,Dawn Hill,Elena Muslimova
Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1-3 selective tyrosine kinase inhibitor in development for achondroplasia.